These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25483495)

  • 1. The relevance of dengue virus genotypes surveillance at country level before vaccine approval.
    Usme-Ciro JA; Méndez JA; Laiton KD; Páez A
    Hum Vaccin Immunother; 2014; 10(9):2674-8. PubMed ID: 25483495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.
    Rabaa MA; Girerd-Chambaz Y; Duong Thi Hue K; Vu Tuan T; Wills B; Bonaparte M; van der Vliet D; Langevin E; Cortes M; Zambrano B; Dunod C; Wartel-Tram A; Jackson N; Simmons CP
    Elife; 2017 Sep; 6():. PubMed ID: 28871961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
    Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
    Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue vaccines: challenges, development, current status and prospects.
    Ghosh A; Dar L
    Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated vaccine: the first clinically approved dengue vaccine?
    Fink K; Shi PY
    Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone.
    Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y
    Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue human infection models to advance dengue vaccine development.
    Larsen CP; Whitehead SS; Durbin AP
    Vaccine; 2015 Dec; 33(50):7075-82. PubMed ID: 26424605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.
    Barban V; Munoz-Jordan JL; Santiago GA; Mantel N; Girerd Y; Gulia S; Claude JB; Lang J
    Virology; 2012 Aug; 429(2):91-8. PubMed ID: 22542002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress in the structure and function of dengue virus non-structural 1 protein].
    Chen Y; Ren RW; Liu JW
    Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in dengue vaccine research and development.
    Miller N
    Curr Opin Mol Ther; 2010 Feb; 12(1):31-8. PubMed ID: 20140814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
    Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
    Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.
    Liang H; Lee M; Jin X
    Cell Mol Immunol; 2016 Jan; 13(1):36-46. PubMed ID: 26435066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.